- Home
- ARQT vs ATRC Comparison
ARQT vs ATRC Comparison
Compare ARQT & ATRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- ATRC
- Stock Information
- Founded
- ARQT 2016
- ATRC 2000
- Country
- ARQT United States
- ATRC United States
- Employees
- ARQT N/A
- ATRC N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- ATRC Medical/Dental Instruments
- Sector
- ARQT Health Care
- ATRC Health Care
- Exchange
- ARQT Nasdaq
- ATRC Nasdaq
- Market Cap
- ARQT 1.1B
- ATRC 1.1B
- IPO Year
- ARQT 2020
- ATRC 2005
- Fundamental
- Price
- ARQT $13.92
- ATRC $36.97
- Analyst Decision
- ARQT Strong Buy
- ATRC Strong Buy
- Analyst Count
- ARQT 5
- ATRC 9
- Target Price
- ARQT $17.00
- ATRC $41.78
- AVG Volume (30 Days)
- ARQT 2.2M
- ATRC 476.9K
- Earning Date
- ARQT 02-25-2025
- ATRC 02-13-2025
- Dividend Yield
- ARQT N/A
- ATRC N/A
- EPS Growth
- ARQT N/A
- ATRC N/A
- EPS
- ARQT N/A
- ATRC N/A
- Revenue
- ARQT $138,708,000.00
- ATRC $447,573,000.00
- Revenue This Year
- ARQT $209.03
- ATRC $17.75
- Revenue Next Year
- ARQT $49.00
- ATRC $13.44
- P/E Ratio
- ARQT N/A
- ATRC N/A
- Revenue Growth
- ARQT 182.84
- ATRC 17.56
- 52 Week Low
- ARQT $3.11
- ATRC $18.94
- 52 Week High
- ARQT $16.20
- ATRC $39.05
- Technical
- Relative Strength Index (RSI)
- ARQT 51.79
- ATRC 66.36
- Support Level
- ARQT $13.10
- ATRC $31.00
- Resistance Level
- ARQT $16.20
- ATRC $34.11
- Average True Range (ATR)
- ARQT 0.95
- ATRC 1.59
- MACD
- ARQT -0.26
- ATRC 0.65
- Stochastic Oscillator
- ARQT 26.45
- ATRC 99.72
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About ATRC AtriCure Inc.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.